Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUND trial of transtympanic sodium thiosulfate for prevention of cisplatin-related hearing loss
NL-OMON59729Phase 3Suspended
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sodium thiosulfate in cisplatin-induced ototoxicity, sponsored by Netherlands Cancer Institute. Primary endpoint: Primary efficacy endpoint. Started Apr 2025; status: suspended.
02
Drugs
sodium thiosulfate
03
Conditions
cisplatin-induced ototoxicity
Beyond the preview
Go deeper on NL-OMON59729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59729.